Clinical Research Committee awards

Clinical Research Funding Scheme

November 2025

CRISTAL-APC: a multi-centre, open label Phase 1/randomised Phase 2 study of VP-002, a C-C motif chemokine receptor 1 inhibitor, given orally in combination with nab-paclitaxel and gemcitabine to patients with advanced pancreatic ductal adenocarcinoma

Dr Bristi Basu

University of Cambridge

Dr Fieke Froeling

University of Glasgow

TRILBY: tracking recurrence with individualised liquid biopsy (formerly immunoREACH/TRACE H&N)

Dr Ben O'Leary

The Institute of Cancer Research

Professor Emma Hall

The Institute of Cancer Research

B5forMDS: a single arm, Phase 2, multi-centre, bayesian, intra-patient dose de-escalation trial to assess the activity of VitB5 for the treatment of patients with SF3B1 mutant MDS

Dr Onima Chowdhury

University of Oxford

Dr Kevin Rouault-Pierre

Barts Cancer Institute, Queen Mary University of London

TRAFIK-CAR: next-generation autologous chimeric antigen receptor T cells for hepatocellular carcinoma

Dr Claire Roddie

University College London

VALTIVE-C: validation of Tie2 for VEGFi in metastatic colorectal cancer

Dr Michael Braun

The Christie NHS Foundation Trust

Professor Gordon Jayson

The Christie NHS Foundation Trust

The University of Manchester

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial programme; RAINBO Translational Research Biobank

Professor Emma Davidson

The University of Manchester

Dr Melanie Powell

Barts Health NHS Trust

rEECur: international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma

Professor Martin McCabe

The University of Manchester

Mr Piers Gaunt

University of Birmingham

Real-world ambispective observational study of molecular responses and clinical outcomes in patients with myeloproliferative neoplasms

Dr Jennifer O'Sullivan

Guy’s and St. Thomas’ NHS Foundation Trust

Dr Alesia Khan

Leeds Teaching Hospitals NHS Trust

A safety and feasibility study investigating the use of non-invasive focused ultrasound with intravenous administration of carboplatin in children, teenagers and young adults diagnosed with progressive/recurrent high-risk brain tumours

Dr Elwira Szychot

Great Ormond Street Hospital for Children NHS Foundation Trust

Professor Antonios Pouliopoulos

King's College London

Professor Darren Hargrave

UCL Great Ormond Street Institute of Child Health

May 2025

SERUM: defining MRD in CR by QIP-MS in blood in the myeloma XV RADAR trial - a blood-based biomarker to enhance patient care (Experimental Medicine module)

Dr I-Jun Lau

University of Oxford

Dr Ross Sadler

Oxford University Hospitals NHS

Sample collection for UK-MRA myeloma XVIII iFIT: immunotherapy approaches adapted for fitness in newly diagnosed transplant ineligible patients with myeloma (Sample Collection module)

Dr Charlotte Pawlyn

Institute of Cancer Research

Professor Gordon Cook

University of Leeds

Explore the Clinical Research Funding Scheme